Prescient

A launch plan can be on track and still be out of date. Throughout the launch journey, competitor activity, new evidence, changing stakeholder expectations and shifts in the access landscape can all influence whether a strategy remains aligned with the market. In their latest article, Sukanya Saha, Associate Partner, and Ryan Caradonna, Global Practice Lead – Partner, at Prescient, explore why a living launch plan is becoming an essential capability for pharmaceutical launch teams, and how competitive intelligence, cross-functional decision-making and governance help organizations recognize meaningful change and keep strategy aligned. Read the article: https://lnkd.in/eNxndttK

Excited to be speaking today at the Pharmaceutical Launch Excellence Summit (#PHLEXUS) in Boston. I'll be sharing insights on Precision Launch: Winning the Moments That Matter Most, exploring how teams can focus on the critical decisions that drive launch success. Looking forward to the discussions and connecting with colleagues. #CommercialStrategy #LaunchExcellence #PrecisionLaunch #prescienthg

Prescribing decisions are shaped by more than clinical evidence alone. In competitive oncology markets, adoption depends on helping oncologists recognise who a therapy is for, when to use it, and why it belongs in routine practice. A clear prescribing heuristic can help build that confidence. In their latest article for PMGroup Worldwide Ltd, PME magazine, Marie Little and Alyssa Burstein explore why identifying the first appropriate patient should be central to commercial planning, and how this can help brands translate strong clinical evidence into meaningful adoption. Read the article: https://lnkd.in/eznPRvaE

Pharma teams are working with more data than ever and still finding it difficult to turn that into confident next steps. In this article, John Grime, Marie Little, Jatin Gupta and Alex Mole explore what it really takes to move from data-rich to decision-ready. The challenge often lies in turning multiple sources and competing signals into a clear, usable direction. In this piece, the Prescient team shares: • Why fragmented insights and competing signals slow progress and make decisions harder to sustain • What integrated insights looks like in practice across teams and data sources • How AI and human expertise work together to support clearer, faster decisions If you are dealing with growing data volumes, competing signals, or pressure to act with confidence, this offers a practical perspective on where to focus next. Read the full article here: https://lnkd.in/eChHkF2g

Despite advances in technology, pharmaceutical launch capability gaps are widening, with more than a third of launch teams telling us that they are still underprepared or underperforming in most areas.  The Prescient Launch Excellence Report 2026 reveals these critical capability gaps across global, regional, and country levels when assessed against seven launch excellence levers. It offers a lens into the competitive landscape, and an opportunity to receive your own analysis, benchmarked against industry standards, with priority areas for improvement and opportunities to strengthen future launch performance identified.   How do your launch capabilities compare? Download the report:   https://lnkd.in/eh8CFTJn    About the report  Classic launch excellence is foundational to Prescient’s Precision Launch approach, which identifies the exact moments, decisions, and strategic levers that have the greatest influence on a specific launch’s success.  The report is developed using anonymized data contributed by launch teams in global, regional, and country-level roles across leading pharmaceutical organizations from January 2025 to date, with insights prepared by Prescient’s Precision Launch experts in September 2026. 

The launch environment is changing fast, and many organizations’ launch strategies aren’t keeping pace.  Scientific innovation, evolving healthcare systems, AI, changing payer expectations and increasingly complex stakeholder environments are reshaping what drives commercial success. In her latest article, Melissa Dagless, Head of Growth – Partner at Prescient, explores why launch archetype and therapy area are becoming two of the strongest determinants of pharmaceutical launch uptake, why every launch demands a tailored strategic approach, and how identifying the must-win moments can help teams focus investment where it will have the greatest impact. Discover why precision in strategic decision-making is becoming an increasingly important determinant of launch success. Read the article: https://lnkd.in/eT6nh8hs

Two weeks to go until Pharmaceutical Launch Excellence Summit US 2026! 🎤 At PHLEX US, Maxine Smith and Melissa Dagless will be taking to the stage to present Precision Launch: Winning the moments that matter most, exploring how teams can identify the decisions that have the greatest influence on a launch and prepare for them with confidence. Attending PHLEX US? Join our session, visit the Prescient booth and, if you'd like to discuss your launch priorities with the team during the event or beyond, book a meeting here: https://lnkd.in/eQEZ943C 📖 For a preview of some of the thinking behind the session, read Maxine's latest article, One-Size-Fits-All Pharma Launches Are Over, here: https://lnkd.in/ezV7_JYs #PHLEXUS #LaunchExcellence #PharmaLaunch #PHLEXUS2026

One-size-fits-all pharma launches are over. Every launch follows a different path. For the launches of tomorrow, the greatest opportunities come from recognizing what matters most and focusing on the decisions that will shape launch performance. In our latest article, Maxine Smith, Head of Practice – Partner, explores how a Precision Launch approach helps teams identify their Must-Win Moments, challenge critical assumptions and adapt with confidence as markets evolve. As Maxine explains: "Launch success depends on being exceptionally ready for the few moments that will determine the trajectory.”    Read the article: https://lnkd.in/ezV7_JYs